Biote Corp. Reports $48.99 Million Revenue in Q1 2025, Achieving 4.7% Growth

Biote Corp. reported a total revenue of $48.99 million for the first quarter of 2025, marking a 4.7% increase from $46.80 million in the same period of the previous year. The growth was primarily driven by a $1.9 million increase in revenue from Biote-branded dietary supplements and a $1.2 million rise in service revenue. Notably, the dietary supplements segment benefited from a strategic shift to e-commerce, particularly through Amazon, which replaced a third-party distributor. Despite these gains, revenue from pellet procedures decreased by $1.3 million due to a slowdown in new clinic additions.

The company's net income for the quarter was $15.84 million, a significant recovery from a net loss of $5.73 million in the prior year. This turnaround was aided by a reduction in the cost of revenue, which fell to $12.61 million from $13.45 million, reflecting cost savings from the vertical integration of Asteria Health, a 503B manufacturer acquired in March 2024. Selling, general, and administrative expenses increased by 16.4% to $26.69 million, driven by higher marketing costs and legal expenses related to ongoing litigation.

Biote's operational metrics showed a stable performance, with cash and cash equivalents rising to $41.70 million from $39.34 million at the end of 2024. The company maintained a strong balance sheet, with total assets of $123.38 million and total liabilities of $208.21 million as of March 31, 2025. The headcount remained consistent, supporting the company's operational needs as it continues to expand its market presence.

Strategically, Biote has focused on enhancing its supply chain through vertical integration, as evidenced by its acquisition of Asteria Health. This move is expected to improve operational efficiency and reduce production costs. Additionally, the company is navigating challenges related to global economic conditions, including inflation and potential supply chain disruptions due to trade policies. Biote's management remains optimistic about future growth, emphasizing the importance of increasing the number of certified practitioners and expanding its product offerings.

Looking ahead, Biote anticipates continued revenue growth driven by its strategic initiatives and market expansion efforts. The company is also preparing for potential restructuring to enhance financial performance, with estimated pre-tax charges of $0.6 million to $0.8 million expected in the second quarter of 2025. Overall, Biote's management is focused on leveraging its unique business model and operational capabilities to capitalize on market opportunities while addressing the challenges posed by the current economic landscape.